GlassScriptPhysician profile
David George Hale
NPI 1598059909
$1,989.89
in general payments reported to CMS, 2019-2025
26 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $191 · 2021: $526 · 2022: $225 · 2023: $107 · 2024: $533 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $435.03 | 2021-2025 | Qelbree |
| Tris Pharma INC | $203.82 | 2019-2025 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $140.68 | 2019-2022 | |
| Cranial Technologies, INC | $139.49 | 2019-2025 | Doc Band |
| Ironshore Pharmaceuticals INC. | $106.11 | 2019-2024 | Jornay Pm |
| Neurelis, INC. | $102.85 | 2024 | Valtoco |
| Phadia US INC. | $101.87 | 2019-2025 | Immunocap |
| Corium, LLC | $100.53 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $90.06 | 2020-2022 | |
| Verrica Pharmaceuticals INC. | $83.42 | 2024 | Ycanth |
| Abbvie INC. | $56.39 | 2020-2022 | |
| Adlon Therapeutics L.P. | $56.33 | 2021 | |
| Photonicare INC | $47.96 | 2023 | Otosight Middle Ear Scope |
| Sanofi Pasteur INC. | $46.68 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $41.09 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.13 | 2022-2024 | M-M-R II, Gardasil, Gardasil 9 |
| Pfizer INC. | $29.89 | 2019-2023 | |
| Ucb, INC. | $27.59 | 2024 | Briviact |
| Neos Therapeutics, LP | $25.73 | 2019 | |
| Acadia Pharmaceuticals INC | $21.50 | 2024 | Daybue |
| Vertical Pharmaceuticals, LLC | $21.33 | 2024 | Relexxii |
| Biogen, INC. | $17.73 | 2021 | |
| Genentech USA, INC. | $17.15 | 2019 | |
| Cipher Pharmaceuticals US LLC | $16.55 | 2025 | Spinosad, Natroba |
| Shire North American Group INC | $15.92 | 2019 | |
| Kaleo, INC. | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.